Active substance
Enflurane
- SFDA 1
- US FDA 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ETHRANE BOTTLE (INHALATION ANESTHESIA) | Inhalation vapour · Oral use | 1 Bottle | SAR 246.50 | NCE · Prescription | Abbott Laboratories | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ETHRANE | 99.9% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | liquid · inhalation | BAXTER HLTHCARE | Discontinued | 28 Aug 1972 |
| ENFLURANE | 99.9% | liquid · inhalation | ABBOTT | Discontinued | 27 Jul 1987 |
| ENFLURANE | 99.9% | liquid · inhalation | PIRAMAL CRITICAL | Discontinued | 29 Jul 1994 |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.